Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerrit Fischedick

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Plos One|April 10, 2012
Zfp296 is a novel, pluripotent-specific reprogramming factorGerrit Fischedick, Diana C Klein, Guangming Wu, et al.
Stem Cell Research|September 1, 2014
Nanog induces hyperplasia without initiating tumorsGerrit Fischedick, Guangming Wu, Kenjiro Adachi, et al.
Nature Cell Biology|August 13, 2013
Establishment of totipotency does not depend on Oct4AGuangming Wu, Dong Han, Yu Gong, et al.
Technical Innovations & Patient Support in Radiation Oncology|May 1, 2026
Do AI-based contouring algorithms influence physicians in the online adaptive radiotherapy of patients with bladder cancer?Nika Guberina, Aymane Khouya, Christian Hoffmann, et al.
Translational Lung Cancer Research|July 17, 2025
The effect of durvalumab consolidation after definitive radiochemotherapy for non-operable stage III non-small cell lung cancer on the dose effect relation for therapy related pulmonary infiltrates as a risk factor for pneumonitisAndreas Herz, Maja Guberina, Christoph Pöttgen, et al.
Diagnostics (Basel, Switzerland)|March 28, 2026
Radiation Dose-Dependent and -Independent Pulmonary Infiltrates in Patients with High-Grade Pneumonitis After Radiochemotherapy and Durvalumab Consolidation for Stage III NSCLCAndreas Herz, Aymane Khouya, Maja Guberina, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Plos One|April 10, 2012
Zfp296 is a novel, pluripotent-specific reprogramming factorGerrit Fischedick, Diana C Klein, Guangming Wu, et al.
Stem Cell Research|September 1, 2014
Nanog induces hyperplasia without initiating tumorsGerrit Fischedick, Guangming Wu, Kenjiro Adachi, et al.
Nature Cell Biology|August 13, 2013
Establishment of totipotency does not depend on Oct4AGuangming Wu, Dong Han, Yu Gong, et al.
Technical Innovations & Patient Support in Radiation Oncology|May 1, 2026
Do AI-based contouring algorithms influence physicians in the online adaptive radiotherapy of patients with bladder cancer?Nika Guberina, Aymane Khouya, Christian Hoffmann, et al.
Translational Lung Cancer Research|July 17, 2025
The effect of durvalumab consolidation after definitive radiochemotherapy for non-operable stage III non-small cell lung cancer on the dose effect relation for therapy related pulmonary infiltrates as a risk factor for pneumonitisAndreas Herz, Maja Guberina, Christoph Pöttgen, et al.
Diagnostics (Basel, Switzerland)|March 28, 2026
Radiation Dose-Dependent and -Independent Pulmonary Infiltrates in Patients with High-Grade Pneumonitis After Radiochemotherapy and Durvalumab Consolidation for Stage III NSCLCAndreas Herz, Aymane Khouya, Maja Guberina, et al.
Pageof 1